📣 VC round data is live. Check it out!

Indegene Valuation Multiples

Discover Indegene's revenue and EBITDA valuation multiples and M&A history, alongside public comparables like iFLYHealth, Schrödinger, CareDx, JMDC and more.

Indegene Overview

About Indegene

Indegene Ltd provides digital-led commercialization services for the life sciences industry, including biopharmaceutical, emerging biotech, and medical device companies. It assists them with drug development and clinical trials, regulatory submissions, pharmacovigilance and complaints management, and the sales and marketing of their products. Its portfolio of solutions covers all aspects of commercial, medical, regulatory, and R&D operations for life sciences companies. The company's segments include Enterprise Medical Solutions, Enterprise Commercial Solutions, Omnichannel Activation, and Others. Key revenue is generated from the Omnichannel Activation segment. The company has a presence in India, Europe, and North America, with the majority of revenue coming from North America.


Founded

1998

HQ

India

Employees

5.0K

Financials (LTM)

Revenue: $384M
EBITDA: $68M

EV

$1B

Valuation Multiples

Start free trial

Valuation Multiples for 15K+ Public Comps

AdidasAirbnbAmazonCiscoCoca-ColaDellDropboxIBMIntelMcDonaldsNikeNVIDIASamsungSpotifyTeslaToyota
Browse Valuation Multiples

Indegene Financials

Indegene reported last 12-month revenue of $384M and EBITDA of $68M.

In the same LTM period, Indegene generated $131M in gross profit, $68M in EBITDA, and $45M in net income.

Revenue (LTM)


Indegene P&L

In the most recent fiscal year, Indegene reported revenue of $370M and EBITDA of $71M.

Indegene is profitable as of last fiscal year, with EBITDA margin of 19% and net margin of 12%.

See analyst estimates for Indegene
LTMLast FY202320242025202620272028
Revenue$384M$370M$265M$292M$352M
Gross Profit$131M---$126M
Gross Margin34%---36%
EBITDA$68M$71M$58M$66M$70M
EBITDA Margin18%19%22%23%20%
EBIT Margin14%14%16%16%14%
Net Profit$45M$43M$34M$41M$42M
Net Margin12%12%13%14%12%

Financial data powered by Morningstar, Inc.

Indegene Stock Performance

Indegene has current market cap of $1B, and enterprise value of $1B.

Market Cap Evolution


Indegene's stock price is $5.37.

Indegene share price decreased by 2.3% in the last 30 days, and by 13.7% in the last year.

Indegene has an EPS (earnings per share) of $0.18.

See more trading valuation data for Indegene
EVMarket CapPrice 1DPrice 1MPrice 3MPrice 12MEPS
$1B$1B-2.3%-2.3%15.3%-13.7%$0.18

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.

Start Free Trial

Indegene Valuation Multiples

Indegene trades at 3.0x EV/Revenue multiple, and 16.8x EV/EBITDA.

See NTM and 2027E valuation multiples for Indegene

EV / Revenue (LTM)


Indegene Financial Valuation Multiples

As of June 2, 2026, Indegene has market cap of $1B and EV of $1B.

Indegene has a P/E ratio of 28.8x.

LTMLast FY202320242025202620272028
EV/Revenue3.0x3.1x4.3x3.9x3.3x
EV/EBITDA16.8x16.3x19.8x17.4x16.4x
EV/EBIT20.7x21.5x26.8x24.4x22.6x
EV/Gross Profit8.8x---9.1x
P/E28.8x30.1x38.4x31.5x30.4x
EV/FCF(139.3x)18.0x27.2x25.2x19.5x

Multiples above and below 250x are considered non-meaningful (n/m). Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Verified Indegene Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.

FactSetMorningstar
Start Free Trial

Indegene Margins & Growth Rates

Indegene grew revenue by 23% and EBITDA by 16% in the last fiscal year.

In the most recent fiscal year, Indegene reported EBITDA margin of 19% and net margin of 12%.

See estimated margins and future growth rates for Indegene

Indegene Margins

Last FY202420252026202720282029
Gross Margin--36%34%
EBITDA Margin19%23%20%18%
EBIT Margin14%16%14%14%
Net Margin12%14%12%12%
FCF Margin17%16%17%12%

Indegene Growth Rates

FY+1/FY23/2424/2525/2626/2727/2828/29
Revenue Growth23%10%20%23%
Gross Profit Growth---16%
EBITDA Growth16%14%6%13%
EBIT Growth23%10%8%22%
Net Profit Growth25%22%3%20%
FCF Growth(22%)8%29%(10%)

Data powered by FactSet, Inc. and Morningstar, Inc.

Indegene Operational KPIs

Indegene's revenue per employee in the last FY averaged $0.1M, while opex per employee averaged $0.1M for the same period.

Indegene's Rule of 40 is 41% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).

Indegene's Rule of X is 75% (created by Bessemer, Rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).

Access forward-looking KPIs for Indegene
LTMLast FY202320242025202620272028
Rule of 4038%41%---
Bessemer Rule of X69%75%---
Revenue per Employee-$0.1M---
Opex per Employee-$0.1M---
G&A Expenses to Revenue--3%3%2%
Opex to Revenue-86%84%84%86%

Data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 230+ Verticals

Indegene Competitors

Indegene competitors include iFLYHealth, Schrödinger, CareDx, JMDC, Vitec Software, Omada Health, Sphere, GeneDx, U.S. Physical Therapy and Certara.

Most Indegene public comparables operate across Healthcare Software, Health Data & Analytics, B2B SaaS, Vertical SaaS and HealthTech.

EV/RevenueEV/EBITDA
Last FYLTM2027ELast FYLTM2027E
iFLYHealth9.5x8.5x(245.4x)(237.7x)
Schrödinger3.5x3.6x(6.4x)(6.4x)
CareDx2.7x2.5x32.0x25.3x
JMDC5.0x3.9x18.1x15.1x
Vitec Software3.5x3.5x8.9x9.3x
Omada Health3.5x3.1x138.8x80.5x
Sphere19.7x-206.0x-
GeneDx3.6x3.4x38.1x61.2x

This data is available for Pro users. Sign up to see all Indegene competitors and their valuation data.

Start Free Trial

Indegene VC Funding History

Before going public, Indegene raised $769M in total equity funding, across 4 rounds.

Last private valuation of Indegene was $700M, after raising $200M in February 2021 from Brighton Park Capital and Carlyle Group.


Indegene Funding Rounds

DateStageRaised FromRaisedValuationRev. MultipleDeal Summary
Jun-25Secondary - publicAbakkus; Eastbridge Group; Premji Invest; Smallcap World Fund; Société Générale$169M--
Feb-21Secondary - privateBrighton Park Capital; Carlyle Group$200M-Indegene Lifesystems is a Bangalore-headquartered enterprise healthtech solutions provider founded in 1998, offering technology platforms and commercialization services to pharmaceutical, biotechnology, and medical device companies to accelerate clinical development, improve regulatory compliance, enhance customer experience, and drive commercial success. The company employs over 3,000 people across North America, Europe, China, Japan, and India. In February 2021, Carlyle Group and Brighton Park Capital agreed to acquire minority stakes in Indegene for US$200 million through a combination of primary investment and secondary sale from existing shareholders. Brighton Park Capital and Carlyle led the deal. Indegene plans to deploy the capital for M&A activities and global expansion.
Feb-21Undisclosed stageBrighton Park Capital; Carlyle Group$200M$700MIndegene is a digital-first life sciences commercialization company providing products and services including AI/ML-led engineering, technology platforms, and analytics services to healthcare and pharmaceutical firms. The company raised $200 million in February 2021 from investors including The Carlyle Group and Brighton Park Capital. This funding supported expansion amid rapid revenue growth. For the fiscal year ending March 31, 2021, Indegene reported revenue of 9.81 billion INR, marking 52.36% year-over-year growth from 6.44 billion INR in FY2020. This period aligns closely with the funding round, reflecting strong traction with net sales of 966.27 crore INR and other income contributing to financial performance. The company demonstrated accelerating growth, with revenue doubling in subsequent years to 16.65 billion INR in FY2022. Indegene's financials show consistent expansion, reaching 28.39 billion INR in revenue by FY2025 with improved margins and profitability. Post-funding, Indegene went public and continued scaling operations, employing over 4,000 people and serving major healthcare clients. The life sciences services market context highlights Indegene's positioning with technology-driven solutions amid industry earnings growth around 20% annually.
Feb-21Undisclosed stageBrighton Park Capital; Carlyle Group$200M-Indegene Lifesystems, a Bangalore-headquartered enterprise healthtech solutions provider founded in 1998 by five first-generation entrepreneurs, received a $200 million investment from The Carlyle Group and Brighton Park Capital in February 2021. The transaction involved Carlyle and Brighton Park acquiring minority stakes through a combination of primary investment into the company and secondary sales from existing shareholders, subject to regulatory approvals. Indegene provides technology platforms and commercialization services to pharmaceutical, biotechnology, and medical device companies, helping clients design, build, and manage digital-first operations leveraging data and automation to accelerate clinical development, improve regulatory compliance, enhance customer experience, and drive commercial success. With over 3,000 employees across North America, Europe, China, Japan, and India, the company had delivered over 100 strategic engagements, managed commercialization of an approximately $2 billion product portfolio, and created over 1 million medical and commercial content assets by that time. The capital was earmarked for mergers and acquisitions as well as global expansion, building on Indegene's history of inorganic growth including acquisitions like SmartCare in 2015 for $6-8 million, Skura Corporation's life sciences business and Encima Group in 2016, and a minority stake sale to Syneos Health in the prior year. Carlyle, with a strong track record in Indian healthcare investments such as Piramal Pharma and SeQuent Scientific, aimed to leverage its global network to support Indegene's portfolio expansion and client relationships. The firm had invested over $13 billion in healthcare globally as of September 2020. Later developments included an IPO filing in India aiming to raise over 32 billion rupees ($386.7 million), where Carlyle and Brighton Park planned to sell shares, and revenues reaching $223.8 million in the 2022 financial year, up 72% year-over-year, but these postdate the 2021 round.

Acquisitions by Indegene

Indegene has acquired 10 companies to date.

Last acquisition by Indegene was on February 18th 2026. Indegene acquired CAKE Kommunikation for $10M (EV/Revenue multiple available to Pro users).

See M&A valuation multiples

Latest Acquisitions by Indegene

CAKE Kommunikation
BioPharm Communications
M J L
Trilogy Writing & Consulting
Description
CAKE Kommunikation is a healthcare marketing agency providing pharmaceutical communications, brand strategy, and medical content for the industry.
BioPharm Communications is a Blue Bell-headquartered agency delivering multichannel campaigns for pharma clients targeting US physicians. It uses Salesforce Marketing Cloud and proprietary HCP data for email, video, and print distribution of clinical trial results. Founded in 2000, the firm serves companies like AstraZeneca and GSK with adherence programs.
M J L is a London-based independent advertising agency focused on biological life sciences and veterinary farming sectors. It delivers integrated campaigns encompassing strategy, creative development, digital marketing, and media planning for pharmaceutical companies, biotech firms, and agribusiness clients. Notable projects include promotional materials for animal health products and medical device launches, with expertise in regulatory-compliant content for EU markets. The agency maintains a portfolio serving clients like veterinary pharmaceutical leaders and crop protection specialists across the UK and Europe.
Trilogy Writing & Consulting is a contract research organization offering regulatory writing services for clinical trials and drug development. Located in Princeton, New Jersey, the firm produces clinical study reports, investigator brochures, protocols, and CTD dossiers compliant with FDA, EMA, and ICH guidelines. Serving biotech, pharma, and medical device clients worldwide, Trilogy supports Phase I-IV studies and has authored documents for over 300 submissions. With a team of PhD-level writers, the company delivers plain-language summaries and health authority responses, accelerating approval timelines.
HQ CountryPhilippinesUnited StatesUnited KingdomGermany
HQ City
-
Philadelphia, PA
Stevenage
Frankfurt
Deal Date18 Feb 20261 Oct 202526 Mar 202527 Mar 2024
Valuation$10M$104M$4M$400K
EV/Revenue
EV/EBITDA

This data is available for Pro users. Sign up to see all Indegene acquisitions and their M&A valuation multiples.

Start Free Trial

Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples

Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.

Start Free Trial

About Indegene

When was Indegene founded?Indegene was founded in 1998.
Where is Indegene headquartered?Indegene is headquartered in India.
How many employees does Indegene have?As of today, Indegene has over 5K employees.
Who is the CEO of Indegene?Indegene's CEO is Manish Gupta.
Is Indegene publicly listed?Yes, Indegene is a public company listed on National Stock Exchange of India.
What is the stock symbol of Indegene?Indegene trades under INDGN ticker.
When did Indegene go public?Indegene went public in 2024.
Who are competitors of Indegene?Indegene main competitors include iFLYHealth, Schrödinger, CareDx, JMDC, Vitec Software, Omada Health, Sphere, GeneDx, U.S. Physical Therapy, Certara.
What is the current market cap of Indegene?Indegene's current market cap is $1B.
What is the current revenue of Indegene?Indegene's last 12 months revenue is $384M.
What is the current revenue growth of Indegene?Indegene revenue growth (NTM/LTM) is 20%.
What is the current EV/Revenue multiple of Indegene?Current revenue multiple of Indegene is 3.0x.
What is the current EBITDA of Indegene?Indegene's last 12 months EBITDA is $68M.
What is Indegene's EBITDA margin?Indegene's last 12 months EBITDA margin is 18%.
What is the current EV/EBITDA multiple of Indegene?Current EBITDA multiple of Indegene is 16.8x.
What is the current FCF of Indegene?Indegene's last 12 months FCF is ($8M).
What is Indegene's FCF margin?Indegene's last 12 months FCF margin is (2%).
What is the current EV/FCF multiple of Indegene?Current FCF multiple of Indegene is (139.3x).
How many companies Indegene has acquired to date?As of June 2026, Indegene has acquired 10 companies.
What was the largest acquisition by Indegene?$104M acquisition of BioPharm Communications on 1st October 2025 was the largest M&A Indegene has done to date.
What companies Indegene acquired?Indegene acquired BioPharm Communications, Encima Group, Medical Marketing Economics, DT Associates, CAKE Kommunikation, SKURA, M J L, Trilogy Writing & Consulting, CultHealth, and Wincere.
In how many companies Indegene has invested to date?Indegene hasn't invested in any companies yet (or none have been disclosed publicly).

See public comps similar to Indegene

Lists including Indegene

Start Your
Free Trial Today

Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.

Start Trial